U.S. Markets open in 9 hrs 23 mins

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,481.00+13.50 (+0.30%)
At close: 4:35PM BST
Full screen
Previous Close4,467.50
Open4,476.50
Bid4,352.00 x 6100
Ask4,535.00 x 13000
Day's Range4,466.50 - 4,525.00
52 Week Range3,996.00 - 5,520.00
Volume1,335,782
Avg. Volume2,202,226
Market Cap56.72B
Beta0.62
PE Ratio (TTM)16.78
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.79 (4.86%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • Reuters7 hours ago

    FDA expands use of AstraZeneca/Merck ovarian cancer drug

    The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive for BRCA genetic mutations associated with high risk for the cancer. The drug was previously approved for treating advanced ovarian cancer in women who had stopped responding to at least three earlier rounds of chemotherapy.

  • Reuters8 hours ago

    FDA approves expanded use of AstraZeneca ovarian cancer drug

    The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive for BRCA genetic mutations associated with high risk for the cancer. The drug was previously approved for treating advanced ovarian cancer in women who had stopped responding to at least three earlier rounds of chemotherapy.

  • TheStreet.com3 days ago

    Shire Gains as it Seeks European Approval For Dry Eye Treatment

    The drug would be the first such treatment in Europe.